1. Universidade Federal do Rio Grande do Norte
  2. Centro de Biociências
  3. DBF - Departamento de Biofísica e Farmacologia
  4. CB - DBF - Artigos publicados em periódicos
Use este identificador para citar ou linkar para este item: https://repositorio.ufrn.br/handle/123456789/25418
Registro completo de metadados
Campo DCValorIdioma
dc.contributor.authorAraújo, Aurigena Antunes de-
dc.contributor.authorChaves, Katarina Melo-
dc.contributor.authorSerrano-Blanco, Antoni-
dc.contributor.authorRibeiro, Susana Barbosa-
dc.contributor.authorSoares, Luiz Alberto Lira-
dc.contributor.authorGuerra, Gerlane Coelho Bernardo-
dc.contributor.authorAlves, Maria do Socorro Costa Feitosa-
dc.contributor.authorAraújo Júnior, Raimundo Fernandes de-
dc.contributor.authorRachetti, Vanessa de Paula Soares-
dc.contributor.authorFilgueira Júnior, Antônio-
dc.date.accessioned2018-06-16T11:41:20Z-
dc.date.available2018-06-16T11:41:20Z-
dc.date.issued2012-07-18-
dc.identifier.citationARAÚJO, Aurigena Antunes de et al. Quality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophrenia. Psychiatric Quarterly, v. 84, p. 125-135, 2012. Disponível em: <https://link.springer.com/article/10.1007%2Fs11126-012-9233-3>. Acesso em: 15 mar. 2018.pt_BR
dc.identifier.issn1573-6709-
dc.identifier.urihttps://repositorio.ufrn.br/jspui/handle/123456789/25418-
dc.languageporpt_BR
dc.publisherSpringerpt_BR
dc.rightsAcesso Abertopt_BR
dc.subjectSchizophreniapt_BR
dc.subjectAtypical antipsychoticpt_BR
dc.subjectQuality of lifept_BR
dc.titleQuality of life and adverse effects of olanzapine versus risperidone therapy in patients with schizophreniapt_BR
dc.typearticlept_BR
dc.identifier.doihttp://dx.doi.org/10.1007/s11126-012-9233-3-
dc.description.resumoThis cross-sectional study aimed to compare the effects of treatment with an atypical antipsychotic drug (olanzapine or risperidone) on quality of life (QoL) and to document adverse effects in 115 patients diagnosed with schizophrenia who attended the ambulatory service of Hospital Dr. João Machado, Natal, Rio Grande do Norte, Brazil. Socioeconomic, sociodemographic, and clinical variables were compared. The QoL Scale validated for Brazil (QLS-BR) was used to evaluate QoL, and adverse effects were assessed using the Udvalg for Kliniske Undersøgelser Side Effect Rating Scale. Data were analyzed using the χ2 test and Student’s t test, with a significance level of 5 %. Patients in both drug groups showed severe impairment in the occupational domain of the QLS-BR. Global QLS-BR scores indicated impairment among risperidone users and severe impairment among olanzapine users. The most significant side effects were associated with risperidone, including asthenia/lassitude/fatigue, somnolence/sedation, paresthesia, change in visual accommodation, increased salivation, diarrhea, orthostatic posture, palpitations/tachycardia, erythema, photosensitivity, weight loss, galactorrhea, decreased sexual desire, erectile/orgasmic dysfunction, vaginal dryness, headache, and physical dependence. QoL was impaired in patients using olanzapine and in those using risperidone. Risperidone use was associated with psychic, neurological, and autonomous adverse effects and other side effects.pt_BR
Aparece nas coleções:CB - DBF - Artigos publicados em periódicos

Arquivos associados a este item:
Arquivo Descrição TamanhoFormato 
QualityLifeAdverseEffects_Araujo_2013.pdf195,05 kBAdobe PDFVisualizar/Abrir
Mostrar registro simples do item


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.